AB56-ASA1-AA2,42,23 83. Page 446, line 1: delete lines 1 and 2 and substitute:

AB56-ASA1-AA2,43,2 “254.151 (2m) Award grants for residential lead hazard abatement, residential lead hazard reduction, and lead abatement worker training.”.

AB56-ASA1-AA2,43,4 84. Page 448, line 25: delete the material beginning with that line and ending with page 449, line 2, and substitute:

AB56-ASA1-AA2,43,5 “ Section 1950m. 255.06 (2) (i) of the statutes is amended to read:

AB56-ASA1-AA2,43,7 255.06 (2) (i) Multiple sclerosis services. Allocate and expend at least up to $60,000 as reimbursement for the provision of multiple sclerosis services to women.”.

AB56-ASA1-AA2,43,8 85. Page 454, line 12: after that line insert:

AB56-ASA1-AA2,43,9 “ Section 2093k. 632.796 of the statutes is created to read:

AB56-ASA1-AA2,43,11 632.796 Drug cost report. (1) Definition. In this section, “disability insurance policy” has the meaning given in s. 632.895 (1) (a).

AB56-ASA1-AA2,43,17 (2) Report required. Annually, at the time the insurer files its rate request with the commissioner, each insurer that offers a disability insurance policy that covers prescription drugs shall submit to the commissioner a report that identifies the 25 prescription drugs that are the highest cost to the insurer and the 25 prescription drugs that have the highest cost increases over the 12 months before the submission of the report.

AB56-ASA1-AA2,2094k Section 2094k. 632.865 (3) of the statutes is created to read:

AB56-ASA1-AA2,43,21 632.865 (3) Registration required. (a) No person may perform any activities of a pharmacy benefit manager in this state without first registering with the commissioner under this subsection.

AB56-ASA1-AA2,43,24 (b) The commissioner shall establish a registration procedure for pharmacy benefit managers. The commissioner may promulgate any rules necessary to implement the registration procedure under this paragraph.

AB56-ASA1-AA2,2095k Section 2095k. 632.866 of the statutes is created to read:

AB56-ASA1-AA2,44,2 632.866 Prescription drug cost reporting. (1) Definitions. In this section:

AB56-ASA1-AA2,44,4 (a) “Brand-name drug” means a prescription drug approved under 21 USC 355 (b) or 42 USC 262.

AB56-ASA1-AA2,44,6 (b) “Covered hospital” means an entity described in 42 USC 256b (a) (4) (L) to (N) that participates in the federal drug-pricing program under 42 USC 256b.

AB56-ASA1-AA2,44,7 (c) “Disability insurance policy” has the meaning given in s. 632.895 (1) (a).

AB56-ASA1-AA2,44,8 (d) “Generic drug” means a prescription drug approved under 21 USC 355 (j).

AB56-ASA1-AA2,44,11 (e) “Manufacturer” has the meaning given in s. 450.01 (12). “Manufacturer” does not include an entity that is engaged only in the dispensing, as defined in s. 450.01 (7), of a brand-name drug or a generic drug.

AB56-ASA1-AA2,44,15 (f) “Manufacturer-sponsored assistance program” means a program offered by a manufacturer or an intermediary under contract with a manufacturer through which a brand-name drug or a generic drug is provided to a patient at no charge or at a discount.

AB56-ASA1-AA2,44,19 (g) “Margin” means, for a covered hospital, the difference between the net cost of a brand-name drug or generic drug covered under the federal drug-pricing program under 42 USC 256b and the net payment by the covered hospital for that brand-name drug or generic drug.

AB56-ASA1-AA2,44,21 (h) “Net payment” means the amount paid for a brand-name drug or generic drug after all discounts and rebates have been applied.

AB56-ASA1-AA2,44,22 (i) “Pharmacy benefit manager” has the meaning given in s. 632.865 (1) (c).

AB56-ASA1-AA2,45,2 (j) “Wholesale acquisition cost” means the most recently reported manufacturer list or catalog price for a brand-name drug or a generic drug available to wholesalers or direct purchasers in the United States, before application of discounts, rebates, or reductions in price.

AB56-ASA1-AA2,45,8 (2) Price increase or introduction notice; justification report. (a) A manufacturer shall notify the commissioner if it is increasing the wholesale acquisition cost of a brand-name drug on the market in this state by more than 10 percent or by more than $10,000 during any 12-month period or if it intends to introduce to market in this state a brand-name drug that has an annual wholesale acquisition cost of $30,000 or more.

AB56-ASA1-AA2,45,12 (b) A manufacturer shall notify the commissioner if it is increasing the wholesale acquisition cost of a generic drug by more than 25 percent or by more than $300 during any 12-month period or if it intends to introduce to market a generic drug that has an annual wholesale acquisition cost of $3,000 or more.

AB56-ASA1-AA2,45,18 (c) The manufacturer shall provide the notice under par. (a) or (b) in writing at least 30 days before the planned effective date of the cost increase or drug introduction with a justification that includes all documents and research related to the manufacturer's selection of the cost increase or introduction price and a description of life cycle management, market competition and context, and estimated value or cost-effectiveness of the product.

AB56-ASA1-AA2,45,22 (3) Net prices paid by pharmacy benefit managers. By March 1 annually, the manufacturer shall report to the commissioner the value of price concessions, expressed as a percentage of the wholesale acquisition cost, provided to each pharmacy benefit manager for each drug sold in this state.

AB56-ASA1-AA2,46,2 (4) Rebates and price concessions. By March 1 annually, each pharmacy benefit manager shall report to the commissioner the amount received from manufacturers as drug rebates and the value of price concessions, expressed as a percentage of the wholesale acquisition cost, provided by manufacturers for each drug.